title: Daily use of sildenafil improves endothelial function in men with type 2 diabetes.
abstract: Diminished vascular endothelial function results in decreased vasodilator  capacity and is associated with erectile dysfunction (ED) in patients  afflicted with type 2 diabetes. The current study was designed to evaluate  whether daily use of sildenafil could alter endothelial function and improve  penile rigidity in a group of patients with diabetic ED. A double-blind,  placebo-controlled, prospective trial was conducted with 24 men with type 2  diabetes who were randomized into 2 groups: one receiving daily sildenafil (50  mg, n = 12) and the other placebo (n = 12) for 10 weeks. Erectile function was  captured subjectively using the International Index of Erectile Function  (IIEF-5), and endothelial function was objectively monitored via brachial  artery flow-mediated dilation. Among the placebo and sildenafil groups, there  were no significant differences in average patient age, time from type 2  diabetes diagnosis, duration of ED, or baseline IIEF-5 scores. Past medical  histories, including smoking, alcohol consumption, hypertension, and  hyperlipidemia, were also similar. At the conclusion of the 10-week trial,  patients who received daily sildenafil had significantly improved erectile  rigidity as captured by IIEF-5 (P < .001) and increased  endothelial function via brachial artery flow-mediated dilation (P  < .01). Endothelial function in men with type 2 diabetes was enhanced with  daily sildenafil. Improved erectile rigidity and enhanced vascular circulation  was noted after 10 weeks of daily sildenafil use.
authors.affiliation: Department of Urology, University of Western Ontario, St Joseph's Hospital, 268 Grosvenor Street, London, Ontario, N6A 4V2, Canada.
authors.forename: Ling
authors.initials: L
authors.lastname: Deyoung
authors.forename: Eric
authors.initials: E
authors.lastname: Chung
authors.forename: Jason R
authors.initials: JR
authors.lastname: Kovac
authors.forename: Walter
authors.initials: W
authors.lastname: Romano
authors.forename: Gerald B
authors.initials: GB
authors.lastname: Brock
mesh_terms: D000368:Aged; D001916:Brachial Artery / Q000187:drug effects* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009864:Ontario; D010410:Penile Erection / Q000187:drug effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D010919:Placebos; D011446:Prospective Studies; D011687:Purines / Q000008:administration & dosage; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D010919:Placebos; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate